New non-invasive technology designed to painlessly measure glucose levels in the human eye shows promise of being able to replace the finger stick blood test, according to the results of a pre-clinical study funded by Freedom Medtech, Inc. The company is a developmental stage medical device company currently focused on the commercialization of novel technologies to use to manage diabetes.
The consumer ready product will operate like binoculars with light being shined on one eye for less than a second and then the digital glucose reading will be displayed on the device. The study involving rabbits showed that the eye scanning technology produced non-invasive, in-vivo glucose measurements tracking blood glucose readings with only a five minute delay.
In addition, through a calibration and validation analysis, the mean absolute percent error for glucose prediction was below 13 percent as compared to an estimate 32 percent error commonly derived from the finger stick blood test. The results of the study were presented at the Biomedical Engineering Society’s 2009 Annual Fall Scientific Meeting.
Craig Misrach, President and CEO of Freedom Meditech said, “We believe that the human eye represents an ideal point of access for the monitoring of bodily glucose without the interferences commonly present in other non-invasive glucose measurement approaches.”
The company performs primary research and development operations throughout Ohio with supporting corporate and engineering activities in San Diego, California. The company is looking to secure $8 million B-round of preferred stock financing and is in the process of interviewing investment banks.
The company is also looking into select partnership arrangements to ideally provide complementary R&D capital, near and long term marketing/sales support, and experience in the distribution and manufacturing of ophthalmic equipment.
For more information, go to www.freedom-meditech.com or call Craig Misrach CEO, (858) 551 0096.
